Corporate Banner
Satellite Banner
qPCR
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Exosome Diagnostics Signs Agreement with Life Technologies

Published: Thursday, June 07, 2012
Last Updated: Thursday, June 07, 2012
Bookmark and Share
Exosome Diagnostics to use the Applied Biosystems® (ABI) 7500 Fast Dx Real-Time PCR Instrument for the Company's exosome biofluid in-vitro diagnostics oncology program.

Exosome Diagnostics plans to validate the ABI instrument platform with exosome biofluid RNA isolation technology kits in upcoming multi-center clinical trials in brain cancer and prostate cancer beginning in 2012.  The ABI 7500 Fast Dx Real-Time PCR Instrument is one of the most widely distributed PCR platforms in laboratories worldwide and is cleared by the Food and Drug Administration.

"Our product development strategy is to match our exosome-based diagnostics technology with the most technically appropriate and widely accepted platforms available," said David Okrongly, chief operating officer of Exosome Diagnostics.  "The ABI 7500 Fast Dx Real-Time PCR Instrument from Life Technologies combines state of the art quantitative PCR (qPCR) technology with broad market and regulatory acceptance, enabling physicians and laboratory customers to efficiently and accurately access diagnostic results."

Ron Andrews, president, Medical Sciences at Life Technologies added, "We are pleased to be partnered with Exosome Diagnostics as they develop their non-invasive cancer diagnostic programs. Our Medical Sciences strategy is focused on partnerships with emerging companies that have promising molecular diagnostic applications that enable the realization of personalized medicine in diseases like cancer."

Exosome Diagnostics is developing a series of urine and blood-based molecular diagnostic tests for use in cancer detection and monitoring.  Exosome Diagnostics' technology provides the ability to isolate a highly pure, stable preparation of ribonucleic acids from biofluids for analysis on existing analytical platforms such as qPCR and next-generation sequencing.  The Company is currently in the process of partnering with various manufacturing groups to provide branded, OEM in-vitro diagnostic solutions for regulatory approval and use in the Company's GLP CLIA-certified laboratory.

"This agreement with Life Technologies continues our pursuit of best-in-class partnerships that include the Prostate Cancer Foundation, Accelerate Brain Cancer Cure and the broad group of leading clinical investigators now collaborating on exosome technology," said James McCullough, chief executive officer of Exosome Diagnostics. "Life Technologies is leading the way in personalized medicine and provides us with the type of customer service and robust technology that are pre-requisites to the successful launch of innovative molecular diagnostics."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Gene Analysis System Could Accelerate Pace of Research on the Space Station
The WetLab-2 system will enable spaceflight genomic studies involving a wide variety of biospecimen types in the unique microgravity environment of space.
Liquid Biopsy for NSCLC
'Liquid biopsy' blood test accurately detects key genetic mutations in most common form of lung cancer, study finds.
Rare DNA Will Have Nowhere To Hide
Two National Institutes of Health grants back Rice University effort to develop new diagnostics.
Seeing Cell to Cell Differences
Seeing differences between individual cells for first time explains symptoms of rare genetic disorders, finds penn study.
Circular RNAs Implicated in Cancer
Circular RNAs – like their protein counterparts – are also affected by genomic rearrangements in cancer, resulting in abnormal fusions.
Know Thy Helicobacter pylori
Non-invasive method for genotyping H.pylori developed.
Zika Test Authorized for Emergency Use
n response to a request from the CDC, the FDA has issued an Emergency Use Authorization (EUA) for a diagnostic tool for Zika virus that will be distributed to qualified laboratories.
Lighting Up Disease-Carrying Mosquitoes
Sandia’s QUASR enables speedy, accurate detection of West Nile and other viruses.
Ultra-Sensitive Test for Cancers, HIV
Test developed that is thousands of times more sensitive than current diagnostics.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!